Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients.

ABSTRACT:

Background

Although the efficacy of molecularly target agents in vitro, their use in routine setting is limited mainly to the use of anti-HER2 and antiEGFR agents in vivo. Moreover, core biopsy of a single cancer site may not be representative of the whole expanding clones and cancer molecular profile at relapse may differ with respect to the primary tumor.

Methods

We assessed the status of a large panel of cancer driver genes by cell-free DNA (cfDNA) analysis in a cohort of 68 patients with 13 different solid tumors at disease progression. Whenever possible, a second cfDNA analysis was performed after a mean of 2.5 months, in order to confirm the identified clone(s) and to check the correlation with clinical evolution.

Results

The approach was able to identify clones

SUBMITTER: Palmieri M 

PROVIDER: S-EPMC7064095 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature